Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Evaluation of Gynecologists' Awareness About Oral Health Condition During Pregnancy in Chennai City.

Paneer S, Muthusamy N, Manickavel RP, Venkatakrishnan CJ, Rathnavelu P, Jayaram M.

J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S331-S334. doi: 10.4103/JPBS.JPBS_24_19.

2.

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.

Chiang CL, Goswami S, Frissora FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2019 Aug 1;134(5):432-444. doi: 10.1182/blood.2018882290. Epub 2019 May 31.

PMID:
31151986
3.

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Greene JT, Mani R, Ramaswamy R, Frissora F, Yano M, Zapolnik K, Harrington B, Wasmuth R, Tran M, Mo X, McKenna M, Rangnekar VM, Byrd JC, Bondada S, Muthusamy N.

Blood Adv. 2019 Apr 23;3(8):1255-1266. doi: 10.1182/bloodadvances.2018025973.

4.

Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.

Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, Mo X, Liu Y, Lapalombella R, Hertlein E, Muthusamy N, Byrd JC.

J Immunol. 2019 May 1;202(9):2806-2816. doi: 10.4049/jimmunol.1801359. Epub 2019 Mar 25.

PMID:
30910862
5.

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684.

6.

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC.

J Clin Invest. 2019 Jan 2;129(1):122-136. doi: 10.1172/JCI99386. Epub 2018 Nov 19.

7.

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.

Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.

Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17.

8.

Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Alhakeem SS, McKenna MK, Oben KZ, Noothi SK, Rivas JR, Hildebrandt GC, Fleischman RA, Rangnekar VM, Muthusamy N, Bondada S.

J Immunol. 2018 Jun 15;200(12):4180-4189. doi: 10.4049/jimmunol.1800241. Epub 2018 Apr 30.

9.

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt GC, Fleischman RA, Durbin EB, Byrd JC, Wang C, Muthusamy N, Rangnekar VM, Bondada S.

Blood. 2018 Jun 28;131(26):2943-2954. doi: 10.1182/blood-2017-10-813931. Epub 2018 Apr 25.

10.

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N.

Oncotarget. 2018 Jan 3;9(11):9706-9713. doi: 10.18632/oncotarget.23880. eCollection 2018 Feb 9.

11.

Foxj1 expressing ependymal cells do not contribute new cells to sites of injury or stroke in the mouse forebrain.

Muthusamy N, Brumm A, Zhang X, Carmichael ST, Ghashghaei HT.

Sci Rep. 2018 Jan 29;8(1):1766. doi: 10.1038/s41598-018-19913-x.

12.

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

13.

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.

Tsai YT, Lakshmanan A, Lehman A, Harrington BK, Lucas FM, Tran M, Sass EJ, Long M, Flechtner AD, Jaynes F, La Perle K, Coppola V, Lozanski G, Muthusamy N, Byrd JC, Grever MR, Lucas DM.

Blood Adv. 2017 Oct 30;1(24):2147-2160. doi: 10.1182/bloodadvances.2017006593. eCollection 2017 Nov 14.

14.

MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.

Pajcini KV, Xu L, Shao L, Petrovic J, Palasiewicz K, Ohtani Y, Bailis W, Lee C, Wertheim GB, Mani R, Muthusamy N, Li Y, Meijerink JPP, Blacklow SC, Faryabi RB, Cherry S, Pear WS.

Sci Signal. 2017 Nov 14;10(505). pii: eaam6846. doi: 10.1126/scisignal.aam6846.

15.

Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.

Oben KZ, Alhakeem SS, McKenna MK, Brandon JA, Mani R, Noothi SK, Jinpeng L, Akunuru S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills HF Jr, St Clair DK, Geiger H, Muthusamy N, Tohyama K, Gupta RC, Bondada S.

Oncotarget. 2017 Aug 24;8(44):77436-77452. doi: 10.18632/oncotarget.20497. eCollection 2017 Sep 29.

16.

Dynein binds and stimulates axonal motility of the endosome adaptor and NEEP21 family member, calcyon.

Shi L, Muthusamy N, Smith D, Bergson C.

Int J Biochem Cell Biol. 2017 Sep;90:93-102. doi: 10.1016/j.biocel.2017.07.005. Epub 2017 Jul 19.

17.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

18.

Ependymal cell contribution to scar formation after spinal cord injury is minimal, local and dependent on direct ependymal injury.

Ren Y, Ao Y, O'Shea TM, Burda JE, Bernstein AM, Brumm AJ, Muthusamy N, Ghashghaei HT, Carmichael ST, Cheng L, Sofroniew MV.

Sci Rep. 2017 Jan 24;7:41122. doi: 10.1038/srep41122.

19.

Developmentally defined forebrain circuits regulate appetitive and aversive olfactory learning.

Muthusamy N, Zhang X, Johnson CA, Yadav PN, Ghashghaei HT.

Nat Neurosci. 2017 Jan;20(1):20-23. doi: 10.1038/nn.4452. Epub 2016 Dec 5.

20.

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.

McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT.

Oncoimmunology. 2016 Sep 9;5(10):e1226720. eCollection 2016.

21.

Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1341. doi: 10.1016/j.bbmt.2016.03.033. Epub 2016 Apr 29. No abstract available.

22.

Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.

Browning RL, Byrd WH, Gupta N, Jones J, Mo X, Hertlein E, Yu L, Muthusamy N, Byrd JC.

Cancer Immunol Res. 2016 Aug;4(8):698-707. doi: 10.1158/2326-6066.CIR-15-0291. Epub 2016 Jun 10.

23.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N.

Vet Comp Oncol. 2017 Sep;15(3):1115-1118. doi: 10.1111/vco.12221. Epub 2016 May 2.

24.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N.

Blood. 2016 Jun 9;127(23):2879-89. doi: 10.1182/blood-2015-11-680546. Epub 2016 Mar 24.

25.

TAK1 determines susceptibility to endoplasmic reticulum stress and leptin resistance in the hypothalamus.

Sai K, Morioka S, Takaesu G, Muthusamy N, Ghashghaei HT, Hanafusa H, Matsumoto K, Ninomiya-Tsuji J.

J Cell Sci. 2016 May 1;129(9):1855-65. doi: 10.1242/jcs.180505. Epub 2016 Mar 16.

26.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd.

Cancer Res. 2016 Apr 15;76(8):2125-36. doi: 10.1158/0008-5472.CAN-15-1490. Epub 2016 Feb 15.

27.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV.

Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

28.

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Apr;22(4):658-668. doi: 10.1016/j.bbmt.2015.12.015. Epub 2015 Dec 29. Erratum in: Biol Blood Marrow Transplant. 2016 Jul;22(7):1341.

29.

An in-depth assessment of India's Mother and Child Tracking System (MCTS) in Rajasthan and Uttar Pradesh.

Gera R, Muthusamy N, Bahulekar A, Sharma A, Singh P, Sekhar A, Singh V.

BMC Health Serv Res. 2015 Aug 11;15:315. doi: 10.1186/s12913-015-0920-2.

30.

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.

Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC.

Am J Hematol. 2015 Nov;90(11):967-9. doi: 10.1002/ajh.24125. Epub 2015 Oct 12.

32.

Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells.

Alhakeem SS, Sindhava VJ, McKenna MK, Gachuki BW, Byrd JC, Muthusamy N, Bondada S.

Ann N Y Acad Sci. 2015 Dec;1362:239-249. doi: 10.1111/nyas.12802. Epub 2015 Jun 11.

33.

MARCKS-dependent mucin clearance and lipid metabolism in ependymal cells are required for maintenance of forebrain homeostasis during aging.

Muthusamy N, Sommerville LJ, Moeser AJ, Stumpo DJ, Sannes P, Adler K, Blackshear PJ, Weimer JM, Ghashghaei HT.

Aging Cell. 2015 Oct;14(5):764-73. doi: 10.1111/acel.12354. Epub 2015 May 25.

34.

ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N.

Exp Hematol. 2015 Sep;43(9):770-4.e2. doi: 10.1016/j.exphem.2015.04.008. Epub 2015 Apr 29.

PMID:
25937048
35.

CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.

Li H, Xu S, Quan J, Yung BC, Pang J, Zhou C, Cho YA, Zhang M, Liu S, Muthusamy N, Chan KK, Byrd JC, Lee LJ, Marcucci G, Lee RJ.

Mol Pharm. 2015 Jun 1;12(6):2010-8. doi: 10.1021/mp5008212. Epub 2015 Apr 28.

36.

Tetraspanins as therapeutic targets in hematological malignancy: a concise review.

Beckwith KA, Byrd JC, Muthusamy N.

Front Physiol. 2015 Mar 23;6:91. doi: 10.3389/fphys.2015.00091. eCollection 2015. Review.

37.

Vaccination coverage in India: a small area estimation approach.

Pramanik S, Muthusamy N, Gera R, Laxminarayan R.

Vaccine. 2015 Mar 30;33(14):1731-8. doi: 10.1016/j.vaccine.2015.01.083. Epub 2015 Feb 11.

PMID:
25681661
38.

Effects of pressure angle and tip relief on the life of speed increasing gearbox: a case study.

Shanmugasundaram S, Kumaresan M, Muthusamy N.

Springerplus. 2014 Dec 16;3:746. doi: 10.1186/2193-1801-3-746. eCollection 2014.

39.

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.

Motiwala T, Kutay H, Zanesi N, Frissora FW, Mo X, Muthusamy N, Jacob ST.

Leukemia. 2015 Jun;29(6):1350-9. doi: 10.1038/leu.2014.341. Epub 2014 Dec 8.

40.

Magnetic tweezers-based 3D microchannel electroporation for high-throughput gene transfection in living cells.

Chang L, Howdyshell M, Liao WC, Chiang CL, Gallego-Perez D, Yang Z, Lu W, Byrd JC, Muthusamy N, Lee LJ, Sooryakumar R.

Small. 2015 Apr 17;11(15):1818-1828. doi: 10.1002/smll.201402564. Epub 2014 Dec 2.

41.

Complementary roles of the neuron-enriched endosomal proteins NEEP21 and calcyon in neuronal vesicle trafficking.

Muthusamy N, Chen YJ, Yin DM, Mei L, Bergson C.

J Neurochem. 2015 Jan;132(1):20-31. doi: 10.1111/jnc.12989. Review.

42.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR.

J Clin Invest. 2014 Nov;124(11):4867-76. doi: 10.1172/JCI75328. Epub 2014 Oct 1.

43.

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.

Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Leukemia. 2015 Feb;29(2):346-55. doi: 10.1038/leu.2014.199. Epub 2014 Jun 20.

44.

Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.

Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA.

J Pharm Biomed Anal. 2014 Sep;98:160-5. doi: 10.1016/j.jpba.2014.05.022. Epub 2014 May 23.

45.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. No abstract available.

46.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC.

MAbs. 2014 May-Jun;6(3):749-55. doi: 10.4161/mabs.28282. Epub 2014 Mar 4.

47.

A knock-in Foxj1(CreERT2::GFP) mouse for recombination in epithelial cells with motile cilia.

Muthusamy N, Vijayakumar A, Cheng G Jr, Ghashghaei HT.

Genesis. 2014 Apr;52(4):350-8. doi: 10.1002/dvg.22753. Epub 2014 Mar 5.

48.

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.

Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC.

Leukemia. 2014 Jun;28(6):1365-8. doi: 10.1038/leu.2014.42. Epub 2014 Jan 23. No abstract available.

49.

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N.

Leukemia. 2014 Jul;28(7):1501-10. doi: 10.1038/leu.2014.32. Epub 2014 Jan 21.

50.

Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.

Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, Huang K, Castro CE, Paulaitis M, Nana-Sinkam SP, Lee LJ.

Anal Chem. 2013 Dec 3;85(23):11265-74. doi: 10.1021/ac401983w. Epub 2013 Nov 13.

Supplemental Content

Loading ...
Support Center